FDA Clearance Tracker · P150048-S092
TRIFORMIS RESILIA Tricuspid Valve
Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Oct 27, 2025
Approved
Time to decision
180 days
Received Apr 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150048-S092
- Device name
- TRIFORMIS RESILIA Tricuspid Valve
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Apr 30, 2025
- Decided
- Oct 27, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150048
Device type
- Device type
- heart-valve, non-allograft tissue (LWR)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the MITRIS RESILIA Mitral Valve for expanding the indications to include the tricuspid position. The device, as modified, will be marketed under the trade name TRIFORMIS RESILIA Tricuspid Valve and is indicated for the replacement of native or prosthetic tricuspid heart valves.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.